Table 2.
Outcome Measures
| Outcome (Mean and 95% CI) | Pregabalin, n = 8 | Placebo, n = 8 |
|---|---|---|
| Overall Pain percent reduction | 33.0 (13.2 - 52.9) | 14.0 (-5.8 to 33.8) |
| Overall Pain VAS reduction | 14.7 (5.1 - 24.3) | 8.5 (-1.1 to 18.1) |
| Allodynia severity, overall percent reduction | 25.2 (0.9 - 49.5) | 30.7 (7.5 - 53.9) |
| Allodynia area, overall percentage reduction | -1.4 (-59.6 to 56.8) | -12.4 (-70.8 to 45.9) |
| Total SF McGill (0-45), premedication | 12.4 (8-25) | 12.3 (7-26) |
| Total SF McGill (0-45), post medication | 7.25 (3-22) | 8.9 (6-16) |
| Side-effects; 0 to 3 | ||
| Sleepiness | 0.7 (0-1.2) | 0.7 (0-1.7) |
| Light-headedness | 0.5 (0-1.6) | 0.2 (0-1.1) |
| Unsteady gait | 0.2 (0 -1.2) | 0.05 (0-0.4) |
| Slowed thinking | 0.2 (0-1) | 0 |
| Headache | 0.01 (0-0.08) | 0.1 (0-0.5) |
| Nausea | 0.1 (0-1) | 0.09 (0-0.4) |
| Vomiting | 0 | 0 |
| Blurry vision | 0.01 (0 -0.08) | 0 |
| Total Side-effect score | 1.7 (0.2 - 3.9) | 1.1 (0-4.1) |